Nova Eye Medical (EYE) Discussion, page-2797

Recent article on iTrack Advance. What I found the most exciting was the bit about closed angle glaucoma. This affects a large number of people, and is the primary type of glaucoma in Asia. However, unlike open angle glaucoma, treatment options are very limited. Up until now there have been no MIGS treatments for these types of patients. However, recent data shows that iTrack Advance, due to its unique mechanism of action, is incredibly effective when it comes to these patients. I've seen the data for closed angle and it seems that this device is even more effective at lowering IOP and drops for this type of glaucoma than it is for open angle (which is significant, as we all know how effective it is for open angle glaucoma). This is quite exciting as not only does it significantly increase the TAM for iTrack Advance, but it will be the only MIGS option available to these patients. This means we have the whole minimally invasive surgical market to ourselves, no competitors! Given that closed angle also tends to be associated with a higher risk of blindness, there is an added impetus for early intervention. Gaining reimbursement and FDA approval for this additional indication could therefore be an additional major near term catalyst event for the share price, which I definitely do not think the current price is valuing at all.